



**PRODUCT
LIST
2024**

**Active
Pharmaceutical
Ingredients**

Under Development Products*

PRODUCT NAME	THERAPY AREA
Abemaciclib	Oncology
Acalabrutinib	Oncology
Adagrasib	Oncology
Alectinib	Oncology
Brigatinib	Oncology
Dabrafenib	Oncology
Daprodustat	Oncology
Darolutamide	Oncology
Deucravacitinib	Plaque Psoriasis
Edoxaban	Cardiovascular
Entrectinib	Oncology
Etrasimod	Ulcerative Colitis
Ferric Maltol	Cardiovascular
Finerenone	Cardiovascular

***Disclaimer:** No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.



PRODUCT NAME	THERAPY AREA
Fruquintinib	Oncology
Fezolinetant	Others
Lurbinectedin	Oncology
Mavacamten	Cardiovascular
Mirogabalin Besylate	Pain Management
Niraparib Tosylate	Oncology
Osimertinib	Oncology
Perfluorohexyloctane	Ophthalmology
Pirtobrutinib	Oncology
Resmetirom	Non-alcoholic steatohepatitis
Ribociclib	Oncology
Ripretinib	Oncology
Ritlecitinib	Dermatology
Tirzepatide	Anti-Diabetic
Treprostinil Olamine	Cardiovascular
Tucatinib	Oncology
Voclosporin	Others

***Disclaimer:** No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Re-imagine
API sourcing
with
Dr.Reddy's

XCEED

Contact us
for more information at
api@drreddys.com

Sign up for our customer
service portal on

<https://api.drreddys.com/customer/signup>

OR



scan the
QR code



Dr.Reddy's 

api.drreddys.com

api@drreddys.com